Granted Patent
B2
US 12,465,583 · App. 18/216,307 · Granted Nov 11, 2025
Methods of treatment using an mTORC1 modulator
Assignee:
Navitor Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to methods, compositions, and unit dosage forms useful for selectively modulating mTORC1 activity.
Claims (23)
1 . A method of treating depression in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a pharmaceutically acceptable composition comprising compound A:
or a pharmaceutically acceptable salt thereof;
wherein the therapeutically effective amount comprises a total daily dose of about 100 mg to about 3000 mg.
2 . The method according to claim 1 , wherein the therapeutically effective amount comprises a total daily dose of about 150 mg, about 300 mg, about 400 mg, about 600 mg, about 800 mg, about 1000 mg, about 1600 mg, about 2400 mg, or about 3000 mg.
3 . The method according to claim 1 , wherein the total daily dose is administered QD.
4 . The method according to claim 1 comprising administering a single dose.
5 . The method according to claim 1 , comprising administering at least two doses.
6 . The method according to claim 1 , comprising administering compound A daily for at least two, three, four, five, six, or seven consecutive days.
7 . The method according to claim 5 , comprising administering a first dose about 48 hours prior to administering a second dose.
8 . The method according to claim 1 , wherein the total daily dose is administered under fasted conditions.
9 . The method according to claim 1 , wherein the total daily dose is administered under fed conditions.
10 . The method according to claim 1 , wherein the depression is treatment-resistant depression (“TRD”).
11 . The method according to claim 1 , wherein the depression is resistant to first line treatments.
12 . The method according to claim 1 , wherein the depression is resistant to second line treatments.
13 . The method according to claim 1 , wherein the patient is diagnosed with major depressive disorder (“MDD”).
14 . The method according to claim 1 , wherein the patient is experiencing a depressive episode and has had at least one inadequate response to at least one antidepressant during the depressive episode.
15 . The method according to claim 1 , wherein the patient is experiencing a depressive episode and has had at least one inadequate response to at least two, three, or four different antidepressants during the depressive episode.
16 . The method according to claim 1 , wherein the patient is assessed to have a Montgomery-Asberg Depression Rating Scale (MADRS) total score of ≥21 prior to treatment.
17 . The method according to claim 1 , wherein the patient is assessed to have a Raskin Depression Rating Scale score of ≥9 prior to treatment.
18 . The method according to claim 1 , wherein administration is oral.
19 . The method according to claim 1 , wherein the total daily dose is a single unit dosage form.
20 . The method according to claim 1 , wherein the total daily dose comprises a liquid unit dosage form comprising about 150 mg, about 300 mg, about 400 mg, about 600 mg, about 800 mg, about 1000 mg, about 1600 mg, about 2400 mg, or about 3000 mg of compound A, or pharmaceutically acceptable salt thereof.
21 . The method according to claim 20 , wherein the total daily dose comprises a liquid unit dosage form comprising about 2400 mg of compound A, or pharmaceutically acceptable salt thereof.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 6, 2026
From: NAVITOR PHARMACEUTICALS, INC.
To: SUPERNUS PHARMACEUTICALS, INC.
Reel/Frame 075552/0122 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 30, 2023
From: LEVENTER, STEVEN; TARGUM, STEVEN D.
To: NAVITOR PHARMACEUTICALS, INC.
Reel/Frame 065380/0665 →
Continuity (3)
Provisional Application
62929449
· Nov 1, 2019
References Cited (286)
US 4110368A
· Floyd, Jr. et al.
· 1978
[cited by applicant]
US 4346110A
· Palfreyman et al.
· 1982
[cited by applicant]
US 4775692A
· Ohno et al.
· 1988
[cited by applicant]
US 5639600A
· McGrath et al.
· 1997
[cited by applicant]
US 6329546B1
· Shiono
· 2001
[cited by applicant]
US 6458781B1
· Connor et al.
· 2002
[cited by applicant]
US 6613934B1
· Jegelka et al.
· 2003
[cited by applicant]
US 6689850B2
· Morini et al.
· 2004
[cited by applicant]
US 6787664B2
· Anderson et al.
· 2004
[cited by applicant]
US 7087648B1
· McGrath
· 2006
[cited by applicant]
US 7390799B2
· Bruncko et al.
· 2008
[cited by applicant]
US 8084456B2
· Burns et al.
· 2011
[cited by applicant]
US 8138347B2
· Knight et al.
· 2012
[cited by applicant]
US 8193228B2
· Chen et al.
· 2012
[cited by applicant]
US 8431608B2
· Christos et al.
· 2013
[cited by applicant]
US 8563549B2
· Burger et al.
· 2013
[cited by applicant]
US 8828987B2
· Borriello et al.
· 2014
[cited by applicant]
US 8895585B2
· Fujiwara et al.
· 2014
[cited by applicant]
US 9315525B2
· Gazic Smilovic et al.
· 2016
[cited by applicant]
US 9434760B2
· Li et al.
· 2016
[cited by applicant]
US 9579284B2
· Zale et al.
· 2017
[cited by applicant]
US 20030203900A1
· Quibell
· 2003
[cited by applicant]
US 20040110982A1
· Anderson et al.
· 2004
[cited by applicant]
US 20070212428A1
· Wittlin
· 2007
[cited by applicant]
US 20100093706A1
· Hauske
· 2010
[cited by applicant]
US 20120219596A1
· Limbach et al.
· 2012
[cited by applicant]
US 20150105386A1
· Mack et al.
· 2015
[cited by applicant]
US 20160137606A1
· Bissantz et al.
· 2016
[cited by applicant]
DE 19623142A1
· 1997
[cited by applicant]
EP 215413A2
· 1987
[cited by applicant]
EP 0372816A1
· 1990
[cited by applicant]
EP 1389617A1
· 2004
[cited by applicant]
EP 2154139A1
· 2010
[cited by applicant]
JP 04048212B
· 1992
[cited by applicant]
WO WO1998008853A1
· 1998
[cited by applicant]
WO WO2000026259A1
· 2000
[cited by applicant]
WO 2000076958A2
· 2000
[cited by applicant]
WO 2003063794A3
· 2003
[cited by applicant]
WO WO2003063794A2
· 2003
[cited by applicant]
WO WO2004019973A1
· 2004
[cited by applicant]
WO WO2004089925A1
· 2004
[cited by applicant]
WO WO2004106328A1
· 2004
[cited by applicant]
WO WO2005007623A2
· 2005
[cited by applicant]
WO WO2005113554A2
· 2005
[cited by applicant]
WO WO2006078846A1
· 2006
[cited by applicant]
WO WO2006117696A2
· 2006
[cited by applicant]
WO WO2006122806A2
· 2006
[cited by applicant]
WO WO2007016176A2
· 2007
[cited by applicant]
WO WO2007044729A2
· 2007
[cited by applicant]
WO WO2007053452A1
· 2007
[cited by applicant]
WO WO2007070514A1
· 2007
[cited by applicant]
WO WO2007084786A1
· 2007
[cited by applicant]
WO WO2007129161A2
· 2007
[cited by applicant]
WO 2008038092A2
· 2008
[cited by applicant]
WO WO2008039218A2
· 2008
[cited by applicant]
WO WO2008044691A1
· 2008
[cited by applicant]
WO WO2008109943A1
· 2008
[cited by applicant]
WO WO2008118802A1
· 2008
[cited by applicant]
WO WO2009114512A1
· 2009
[cited by applicant]
WO 2011092128A1
· 2011
[cited by applicant]
WO WO2011102964A1
· 2011
[cited by applicant]
WO 2012113847A1
· 2012
[cited by applicant]
WO 2013052393A1
· 2013
[cited by applicant]
WO 2013064703A2
· 2013
[cited by applicant]
WO WO2013142229A1
· 2013
[cited by applicant]
WO WO2014127052A1
· 2014
[cited by applicant]
WO 2014145852A2
· 2014
[cited by applicant]
WO WO2014201111A1
· 2014
[cited by applicant]
WO 2016040824A2
· 2016
[cited by applicant]
WO WO2017070518A1
· 2017
[cited by applicant]
WO WO2017083823A1
· 2017
[cited by applicant]
WO 2017185010A1
· 2017
[cited by applicant]
WO WO2018200625A1
· 2018
[cited by applicant]
WO WO2020086816A1
· 2020
[cited by applicant]
WO 2021087432A1
· 2021
[cited by applicant]
Brenner et al., “Synthesis and CD Spectr in MeCN, MeOH, and H
[cited by applicant]
Jung et al., “Synthesis of 3-Substituted and 3, 4-Disubstituted Pyrazolin-5-Ones,” Tetrahedron, 2002, vol. 58, pp. 3639-3646.
[cited by applicant]
Koot et al., “Synthesis of Statine From (S)-Malic Acid; Stereocontrol via Radical Cyclization,” Tetrahedron Letters, 1991, vol. 32, No. 3, pp. 401-404.
[cited by applicant]
Ojima et al., “New Synthesis of Nitrogen Heterocycles Through Amide-Directed Hydrocarbonylation . . . ,” J. Org. Chem., 1991, vol. 56, pp. 2024-2030.
[cited by applicant]
Visualization Bioactivity: (3r, 5S)-3-Hydroxy-5-isobutyl-pyrrolidin-2-one, Jan. 1, 2001, pp. 1-2, XP093022482.
[cited by applicant]
Visualization Bioactivity: 5-isobutyl-1, 2-dihydro-pyrazol-3-one, Jan. 1, 1901, pp. 1-4, XP093022481.
[cited by applicant]
Braga, D., “Crystal Polymorphism and Multiple Crystal Forms,” Struct. Bond, 2009, vol. 132, pp. 25-50.
[cited by applicant]
Hilfker, R., “Relevance of Solid-State Properties for Pharmaceutical Products,” Polymorphism in the Pharmaceutical Industry, 2006, pp. 1-19.
[cited by applicant]
Chemical Abstract Registry No. 1892397-17-9, indexed in the Registry File on STN CAS Online Apr. 18, 2016.
[cited by applicant]
Chemical Abstract Registry No. 1865561-59-6, indexed in the Registry File on STN CAS Online Feb. 12, 2016.
[cited by applicant]
Chemical Abstract Registry No. 1864740-65-7, indexed in the Registry File on STN CAS Online Feb. 11, 2016.
[cited by applicant]
Kato Taro et al., “Sestrin modulator NV-5138 produces rapid antidepressant effects via direct mTORC1 activation”, Journal of Clinical Investigation, 129/6, pp. 2542-2554, May 20, 2019.
[cited by applicant]
Navitor's Three Phase 1 Studies for NV-5138 Show Antidepressant Effects and Biomarker Impact, Supporting Further Development of Direct Activator of mTORC1 in Depression Sep. 12, 2019.
[cited by applicant]
Abe et al., “Mammalian target of Rapa,ycin (mTOR) Activation Increases Axonal Growth Capacity of Injured Peripheral Nerves,” J Biol Chem. 2010;285(36):28034-43.
[cited by applicant]
Ali et al., “IL-15-PI3K-AKT-mTOR: A Critical Pathway in the Life Journey of Natural Killer Cells,” Front Immunol. 2015;6:355.
[cited by applicant]
Andrzejewska et al., “Cystinosin is a Component of the Vacuolar H+-ATPase-Ragulator-Rag Complex Controlling Mammalian Target of Rapamycin Complex 1 Signaling,” J Am Soc Nephrol. 2016;27(6):1678-88.
[cited by applicant]
Bar-Peled and Sabatini, “Regulation of mTORC1 by amino acids,” Trends Cell Biol. 2014;24(7):400-6.
[cited by applicant]
Bar-Peled et al., “A Tumor suppressor complex with GAP activity for the RAG GTPases that signal amino acid sufficiency to mTORC1,” Science. 2013;340(6136):1100-6.
[cited by applicant]
Bar-Peled et al., “Ragulator is a GEF for the rag GTPases that signal amino acid levels to mTORC1,” Cell. Sep. 14, 2012;150(6):1196-208.
[cited by applicant]
Berge et al., “Pharmaceutical salts,” J Pharm Sci. 1977;66(1):1-19.
[cited by applicant]
Bidinosti et al., “CLK2 inhibition ameliorates autistic features associated with SHANK3 deficiency,” Science. Mar. 11, 2016;351(6278):1199-203.
[cited by applicant]
Bowling et al., “Antipsychotics Activate mTORC1-Dependent Translation to Enhance Neuronal Morphological Complexity,” Sci Signal. Jan. 14, 2014;7(308):ra4.
[cited by applicant]
Brugarolas et al., “Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex,” Genes Dev. Dec. 1, 2004;18(23):2893-904.
[cited by applicant]
Buckbinder et al., “Gene regulation by temperature-sensitive p53 mutants: identification of p53 response genes,” Proc Natl Acad Sci U S A. Oct. 25, 1994; 91(22):10640-4.
[cited by applicant]
Budanov and Karin, “The p53 target genes sestrinl and sestrin2 connect genotoxic stress and mTOR signaling,” Cell. Aug. 8, 2008;134(3):451-60.
[cited by applicant]
Buerger et al., “Localization of Rheb to the endomembrane is critical for its signaling function,” Biochem Biophys Res Commun. Jun. 9, 2006;344(3):869-80.
[cited by applicant]
Bull et al., “Conjugate additions of organocuprates to a 3-methylene-6-isopropyldiketopiperazine acceptor for the asymmetric synthesis of homochiral a-amino acids,” J Chem Soc Perkin 1. 2001;3281-7.
[cited by applicant]
Bures et al., “Chiral imidazole derivatives synthesis from enantiopure N-protected a-amino acids,” Tetrahedron Asymmetry. Jan. 2005;16(7):1347-54.
[cited by applicant]
Cao et al., “Autophagy Is Disrupted in a Knock-in Mouse Model of Juvenile Neuronal Ceroid Lipofuscinosis,” J Biol Chem. Jul. 21, 2006;281(29):20483-93.
[cited by applicant]
Cao et al., “Translational control of entrainment and synchrony of the suprachiasmatic circadian clock by mTOR/4E-BP1 signaling,” Neuron. Aug. 21, 2013;79(4):712-24.
[cited by applicant]
CAS STN Abstract RN 1779709-85-1, entered Jun. 14, 2015.
[cited by applicant]
CAS STN Abstract, RN 1378266-29-5 (Pub. Jun. 14, 2012).
[cited by applicant]
CAS STN Abstract, RN 1555441-22-9 (Pub. Feb. 25, 2014).
[cited by applicant]
CAS STN Abstract, RN 1698493-03-6 (Pub. May 5, 2015).
[cited by applicant]
CAS STN Abstract, RN 1780718-09-3 (Pub. Jun. 15, 2015).
[cited by applicant]
Chantranupong et al., “The Sestrins interact with GATOR2 to negatively regulate the amino-acid-sensing pathway upstream of mTORC1,” Cell Rep. Oct. 9, 2014;9(1):1-8.
[cited by applicant]
Chauhan et al., “Muscle-specific regulation of the mTOR signaling pathway in MuSK antibody seropositive (MuSK+) experimental autoimmune Myasthenia gravis (EAMG),” Neurosci Res. Sep.-Oct. 2013;77(1-2):102-9.
[cited by applicant]
Chen et al., “Design, Synthesis, Activity, and Structure of a Novel Class of Matrix Metalloproteinase Inhibitors containing a Heterocyclic P2-P3 Amide Bond Isotere,” Bioorg Med Chem Lett. 1996;6(13):1601-6.
[cited by applicant]
Chi, “Regulation and function of mTOR signaling in T cell fate decisions,” Nat Rev Immunol. Apr. 20, 2012;12(5):325-38.
[cited by applicant]
Child et al., “Cardiac mTORC1 Dysregulation Impacts Stress Adaptation and Survival in Huntington's Disease,” Cell Rep. Apr. 24, 2018;23(4):1020-1033.
[cited by applicant]
Ching et al., “mTOR dysfunction contributes to vacuolar pathology and weakness in valosin-containing protein associated inclusion body myopathy,” Hum Mol Genet. Mar. 15, 2013;22(6):1167-79.
[cited by applicant]
Cuthbertson et al., “Anabolic signaling deficits underlie amino acid resistance of wasting, aging muscle,” FASEB J. Mar. 2005;19(3):422-4.
[cited by applicant]
Deboves et al, “A new route to hydrophobic amino acids using copper-promoted reactions of serine-derived organozinc reagents,” J Chem Soc Perkin 1. 2000;4284-92.
[cited by applicant]
Delgoffe et al., “The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment,” Immunity. Jun. 19, 2009;30(6):832-44.
[cited by applicant]
Di Polo, “Dendrite pathology and neurodegeneration: focus on mTOR,” Neural Regen Res. Apr. 2015;10(4):559-61.
[cited by applicant]
Dibble et al., “TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1m,” Mol Cell. Aug. 24, 2012;47(4):535-46.
[cited by applicant]
Efeyan et al., “Amino acids and mTORC1: from lysosomes to disease,” Trends Mol Med. Sep. 2012;18(9):524-33.
[cited by applicant]
Fossale et al., “Membrane trafficking and mitochondrial abnormalities precede subunit c deposition in a cerebellar cell model of juvenile neuronal ceroid lipofuscinosis,” BMC Neurosci. Dec. 10, 2004;5:57.
[cited by applicant]
Garami et al., “Insulin Activation of Rheb, a Mediator of mTOR/S6K/4E-BP Signaling, Is Inhibited by TSC1 and 2,” Mol Cell. Jun. 2003;11(6):1457-66.
[cited by applicant]
Gordon et al., “Regulation of muscle protein synthesis and the effects of catabolic states,” Int J Biochem Cell Biol. Oct. 2013;45(10):2147-57.
[cited by applicant]
Gurpur et al., “Valproic acid activates the PI3K/Akt/mTOR pathway in muscle and ameliorates pathology in a mouse model of Duchenne muscular dystrophy,” Am J Pathol. Mar. 2009;174(3):999-1008.
[cited by applicant]
Ham et al., “Leucine as a treatment for muscle wasting: A critical review,” Clin Nutr. Dec. 2014;33(6):937-45.
[cited by applicant]
Hirose et al., “RagA is a functional homologue of S. cerevisiae Gtr1p involved in the Ran/Gsp1-GTPase pathway,” J Cell Sci. Jan. 1998;111 ( Pt 1):11-21.
[cited by applicant]
Howell et al., “A growing role for mTOR in promoting anabolic metabolism,” Biochem Soc Trans. Aug. 2013;41(4):906-12.
[cited by applicant]
Ignácio et al., “New perspectives on the involvement of mTOR in depression as well as in the action of antidepressant drugs,” Br J Clin Pharmacol. Nov. 27, 2015;82(5):1280-1290.
[cited by applicant]
Inoki et al., “Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling,” Genes Dev. Aug. 1, 2003;17(15):1829-34.
[cited by applicant]
Ito et al., “A medium-term rat liver bioassay for rapid in vivo detection of carcinogenic potential of chemicals,” Cancer Sci. Jan. 2003;94(1):3-8.
[cited by applicant]
Ivanova et al., “Altered mTOR signalling in nephropathic cystinosis,” J Inherit Metab Dis. May 2016;39(3):457-464.
[cited by applicant]
Kang et al., “mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin,” Science. Jul. 26, 2013;341(6144):1236566.
[cited by applicant]
Katholnig et al., “Immune responses of macrophages and dendritic cells regulated by mTOR signaling,” Biochem Soc Trans. Aug. 2013;41(4):927-33.
[cited by applicant]
Kim and Guan, “mTOR: a pharmacologic target for autophagy regulation,” J Clin Invest. Jan. 2015;125(1):25-32.
[cited by applicant]
Kim et al., “Nutrient regulation of the mTOR complex 1 signaling pathway,” Mol. Cells. 2013;35(6):463-73.
[cited by applicant]
Kim et al., “Regulation of TORC1 by Rag GTPases in nutrient response,” Nat Cell Biol. Aug. 2008;10(8):935-45.
[cited by applicant]
Kye et al., “SMN regulates axonal local translation via miR-183/mTOR pathway,” Hum Mol Genet. Dec. 1, 2014;23(23):6318-31.
[cited by applicant]
Köhler et al., “Inflammation in Depression and the Potential for Anti-Inflammatory Treatment,” Curr Neuropharmacol. 2016;14(7):732-42.
[cited by applicant]
Lambe et al., “Hypocretin (orexin) induces calcium transients in single spines postsynaptic to identified thalamocortical boutons in prefrontal slice,” Neuron. Sep. 25, 2003;40(1):139-50.
[cited by applicant]
Laplante and Sabatini, “mTOR signaling in growth control and disease,” Cell. Apr. 13, 2012;149(2):274-93.
[cited by applicant]
Lee et al., “Functional effects of a pathogenic mutation in Cereblon (CRBN) on the regulation of protein synthesis via the AMPK-mTOR cascade,” J Biol Chem. Aug. 22, 2014;289(34):23343-52.
[cited by applicant]
Lee et al., “Platelets support extracellular sialylation by supplying the sugar donor substrate,” J Biol Chem. Mar. 28, 2014;289(13):8742-8.
[cited by applicant]
Lee et al., “Reinstating aberrant mTORC1 activity in Huntington's disease mice improves disease phenotypes,” Neuron. Jan. 21, 2015;85(2):303-15.
[cited by applicant]
Lehnert, “Knoevenagel-Kondensation Mit TiCl4/Base-V, 3-Alkyliden-und-3-Aryliden-2,4-Pentandione aus Aldehyden und Acetylaceton,” Synthesis. 1974:667-669.
[cited by applicant]
Li et al., “Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure,” Biol Psychiatry. Apr. 15, 2011;69(8):754-61.
[cited by applicant]
Li et al., “mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists,” Science. Aug. 20, 2010;329(5994):959-64.
[cited by applicant]
Liebau et al., “Dysregulated autophagy contributes to podocyte damage in Fabry's disease,” PLoS One. May 17, 2013;8(5):e63506.
[cited by applicant]
Lin et al., “Activation of mTOR Ameliorates Fragile X Premutation rCGG Repeat-Mediated Neurodegeneration,” PLoS One. Apr. 23, 2013;8(4):e62572.
[cited by applicant]
Liu et al., “GLYX-13 Produces Rapid Antidepressant Responses with Key Synaptic and Behavioral Effects Distinct from Ketamine,” Neuropsychopharmacology. May 2017;42(6):1231-1242.
[cited by applicant]
Liu et al., “Hypocretins (orexins) regulate serotonin neurons in the dorsal raphe nucleus by excitatory direct and inhibitory indirect actions,” J Neurosci. Nov. 1, 2002;22(21):9453-64.
[cited by applicant]
Long et al., “Rheb binds and regulates the mTOR kinase,” Curr Biol. Apr. 26, 2005;15(8):702-13.
[cited by applicant]
Love, “Demyelinating diseases,” J Clin Pathol. Nov. 2006;59(11):1151-9.
[cited by applicant]
Léger et al., “Atrogin-1, MuRF1, and FoXO, as well as phosphorylated GSK-3beta and 4E-BP1 are reduced in skeletal muscle of chronic spinal cord-injured patients,” Muscle Nerve. Jul. 2009;40(1):69-78.
[cited by applicant]
Macovei et al., “Polyclonal antibodies: a cheap and efficient tool for screening of enantioselective catalysts,” Chem Commun. May 11, 2012;48(37):4411-13.
[cited by applicant]
Malkesman et al., “The female urine sniffing test: a novel approach for assessing reward-seeking behavior in rodents,” Biol Psychiatry. May 1, 2010;67(9):864-71.
[cited by applicant]
Manzi and Wasko, “Inflammation-mediated rheumatic diseases and atherosclerosis,” Ann Rheum Dis. May 2000;59(5):321-5.
[cited by applicant]
McVey et al., “CHO cells knocked out for TSC2 display an improved productivity of antibodies under fed batch conditions,” Biotechnol Bioeng. Sep. 2016;113(9):1942-52.
[cited by applicant]
Nagamori et al., “Structure-Activity Relations of Leucine Derivatives Reveal Critical Moieties for Cellular Uptake and Activation of mTORC1-Mediated Signaling,” Amino Acids, 2016, vol. 48, No. 4, pp. 1045-1048.
[cited by applicant]
Nakamura et al., “Role of the mTOR complex 1 pathway in the in vivo maintenance of the intestinal mucosa by oral intake of amino acids,” Geriatr Gerontol Int. Jan. 2012;12(1):131-9.
[cited by applicant]
Napolitano et al., “Impairment of chaperone-mediated autophagy leads to selective lysosomal degradation defects in the lysosomal storage disease cystinosis,” EMBO Mol Med. Feb. 2015;7(2):158-74.
[cited by applicant]
National Center for Biotechnology Information. PubChem Substance Record for SID 219681321, AKOS024124980, Source: AKos Consulting & Solutions. https://pubchem.ncbi.nlm.nih.gov/substance/219681321. Accessed Nov. 22, 2016.
[cited by applicant]
National Center for Biotechnology Information. PubChem Substance Record for SID 4757389, SID 4757389, Source: ChemDB. https://pubchem.ncbi.nlm.nih.gov/substance/4757389. Accessed Feb. 16, 2017.
[cited by applicant]
National Center for Biotechnology Information. PubChem Substance Record for SID 8685219, SID 8685219, Source: DiscoveryGate. https://pubchem.ncbi.nlm.nih.gov/substance/8685219. Accessed Nov. 22, 2016.
[cited by applicant]
Nelson et al., “Autophagy-lysosome pathway associated neuropathology and axonal degeneration in the brains of alpha-galactosidase A-deficient mice,” Acta Neuropathol Commun. Feb. 14, 2014;2(20).
[cited by applicant]
Nobukuni et al., “Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase,” Proc Natl Acad Sci U S A. Oct. 4, 2005;102(40):14238-43.
[cited by applicant]
Norrmén et al., “mTORC1 controls PNS myelination along the mTORC1-RXR-SREBP-lipid biosynthesis axis in Schwann cells,” Cell Rep. Oct. 23, 2014;9(2):646-60.
[cited by applicant]
Novarino et al., “Mutations in BCKD-kinase lead to a potentially treatable form of autism with epilepsy,” Science. Oct. 19, 2012;338(6105):394-7.
[cited by applicant]
O'Brien et al., “Regulation of T-cell survival and mitochondrial homeostasis by TSC1,” Eur J Immunol. Nov. 2011;41(11):3361-70.
[cited by applicant]
Panchaud et al., “Amino Acid Deprivation Inhibits TORC1 Through a GTPase-Activating Protein Complex for the Rag Family GTPase Gtr1,” Sci Signal. May 28, 2013;6(277):ra42.
[cited by applicant]
Park et al., “TSC1 regulates the balance between effector and regulatory T cells,” J Clin Invest. Dec. 2013;123(12):5165-78.
[cited by applicant]
Pasiakos et al., “Leucine-enriched essential amino acid supplementation during moderate steady state exercise enhances postexercise muscle protein synthesis,” Am J Clin Nutr. Sep. 2011;94(3):809-18.
[cited by applicant]
Payne et al., “L-Leucine improves the anemia and developmental defects associates with Diamond-Blackfan anemia and del(5q) MDS by activating the mTOR pathway,” Blood. Sep. 13, 2012;120(11):2214-24.
[cited by applicant]
PCT International Search Report and Written Opinion from PCT/US2018/029288, dated Jun. 14, 2018.
[cited by applicant]
PCT International Search Report and Written Opinion from PCT/US2019/057815, dated Jan. 6, 2020.
[cited by applicant]
PCT International Search Report and Written Opinion from PCT/US2020/058475, dated Feb. 1, 2021.
[cited by applicant]
Pearce et al., “Action of BTN1, the yeast orthologue of the gene mutated in Batten disease,” Nat Genet. May 1999;22(1):55-8.
[cited by applicant]
Pedroso et al., “Reviewing the Effects of L-Leucine Supplementation in the Regulation of Food Intake, energy Balance, and Glucose Homeostasis,” Nutrients. May 22, 2015;7(5):3914-37.
[cited by applicant]
Peeters et al., “PA26 is a candidate gene for heterotaxia in humans: identification of a novel PA26-related gene family in human and mouse,” Hum Genet. May 2003;112(5-6):573-80.
[cited by applicant]
Pelà et al., “Racemic synthesis and solid phase peptide synthesis application of the chimeric valine/leucine derivative 2-amino-3,3,4-trimethyl-pentanoic acid,” Pharmazie. 2014;69(7):496-9.
[cited by applicant]
Peng et al., “Sestrins function as guanine nucleotide dissociation inhibitors for Rag GTPases to control mTORC1 signaling,” Cell. Sep. 25, 2014;159(1):122-133.
[cited by applicant]
Pollizzi et al., “mTORC1 and mTORC2 selectively regulate CD8+ T cell differentiation,” J Clin Invest. May 2015;125(5):2090-108.
[cited by applicant]
Punzo et al., “Stimulation of the insulin/, TOR pathway delays cone death in a mouse model of retinitis pigmentosa,” Nat Neurosci. Jan. 2009;12(1):44-52.
[cited by applicant]
Rennie, “Anabolic resistance: the effects of aging, sexual dimorphism, and immobilization on human muscle protein turnover,” Appl Physiol Nutr Metab. Jun. 2009;34(3):377-81.
[cited by applicant]
Roccio et al., “Regulation of the small GTPase Rheb by amino acids,” Oncogene. Feb. 2, 2006;25(5):657-64.
[cited by applicant]
Saito et al., “Novel role of the small GTPase Rheb: its implication in endocytic pathway independent of the activation of mammalian target of rapamycin,” J Biochem. Mar. 2005;137(3):423-30.
[cited by applicant]
Sancak et al., “Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids,” Cell. Apr. 16, 2010;141(2):290-303.
[cited by applicant]
Sancak et al., “The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1,” Science. Jun. 13, 2008;320(5882):1496-501.
[cited by applicant]
Saucedo et al., “Rheb promotes cell growth as a component of the insulin/TOR signalling network,” Nat Cell Biol. Jun. 2003;5(6):566-71.
[cited by applicant]
Schürmann et al., “Cloning of a Novel Family of Mammalian GTP-binding Proteins (RagA, RagBs, RagB1) with Remote Similarity to the Ras-related GTPases,” J Biol Chem. Dec. 1, 1995;270(48):28982-8.
[cited by applicant]
Sekiguchi et al., “Novel G Proteins, Rag C and Rag D, Interact with GTP-binding Proteins, Rag A and Rag B,” J Biol Chem. Mar. 9, 2001;276(10):7246-57.
[cited by applicant]
Smith et al., “The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses,” J Biol Chem. May 13, 2005;280(19):18717-27.
[cited by applicant]
Song et al., “A simple method for preparation of N-mono- and N,N-di-alkylated a-amino acids,” Tetrahedron Lett. 2000;41:8225-30.
[cited by applicant]
Song et al., “mTOR attenuates the inflammatory response in cardiomyocytes and prevents cardiac dysfunction in pathological hypertrophy,” Am J Physiol Cell Physiol. Dec. 2010;299(6):C1256-66.
[cited by applicant]
Stein et al., “Protein kinetics during and after long-duration spaceflight on MIR,” Am J Physiol. Jun. 1999;276(6 Pt 1):E1014-21.
[cited by applicant]
Stocker et al., “Rheb is an essential regulator of S6K in controlling cell growth in
[cited by applicant]
Takikita et al., “Pertubed myelination process of premyelinating oligodendrocyte in Niemann-Pick type C mouse,” J Neuropathol Exp Neurol. Jun. 2004;63(6):660-73.
[cited by applicant]
Tarlungeanu et al., “Impaired Amino Acid Transport at the Blood Brain Barrier Is a Cause of Autism Spectrum Disorder,” Cell. Dec. 1, 2016;167(6):1481-1494.e18.
[cited by applicant]
Tee et al., “Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling,” Proc Natl Acad Sci U S A. Oct. 15, 2002;99(21):13571-6.
[cited by applicant]
Tsun et al., “The folliculin tumor suppressor is a GAP for the RagC/D GTPases that signal amino acid levels to mTORC1,” Mol Cell. Nov. 21, 2013;52(4):495-505.
[cited by applicant]
Tyler et al., “Activation of the mammalian target of rapamycin (mTOR) is essential for oligodendrocyte differentiation,” J Neurosci. May 13, 2009;29(19):6367-78.
[cited by applicant]
Vergarajauregui et al., “Autophagic dysfunction in mucolipidosis type IV patients,” Hum Mol Genet. Sep. 1, 2008;17(17):2723-37.
[cited by applicant]
Wang et al., “Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1,” Science. Jan. 9, 2015;347(6218):188-94.
[cited by applicant]
Wang et al., “The amino acid transporter SLC38A9 is a key component of a lysosomal membrane complex that signals arginine sufficiency to mTORC1,” Science, vol. 347, No. 6218, Jan. 2015 (pp. 188-194).
[cited by applicant]
Wang et al., “Tuberous sclerosis 1 (Tsc1)-dependent metabolic checkpoint controls development of dendritic cells,” Proc Natl Acad Sci U S A. Nov. 26, 2013;110(50):E4894-903.
[cited by applicant]
Warner-Schmidt and Duman, “VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants,” Proc Natl Acad Sci U S A. Mar. 13, 2007;104(11):4647-52.
[cited by applicant]
Wolfson et al., “Sestrin2 is a leucine sensor for the mTORC1 pathway,” Science. Jan. 1, 2016;351(6268):43-8.
[cited by applicant]
Wong et al., “
[cited by applicant]
Xu et al., “A Mental Retardation-linked Nonsense Mutation in Cereblon Is Rescued by Proteasome Inhibition,” J Biol Chem. Oct. 11, 2013;288(41):29573-85.
[cited by applicant]
Xu et al., “Improved transcription and translation with L-leucine stimulation of mTORC1 in Roberts syndrome,” BMC Genomics. 2016;17(25).
[cited by applicant]
Yang et al., “Reduced Excitatory Neurotransmission and Mild Autism-Relevant Phenotypes in Adolescent Shank3 Null Mutant Mice,” J Neurosci. May 9, 2012;32(19):6525-41.
[cited by applicant]
Yang et al., “The tumor suppressor Tscl enforces quiescence of naive T cells to promote immune homeostasis and function,” Nat Immunol. Jul. 17, 2011;12(9):888-97.
[cited by applicant]
Ye et al., “Chemical aminoacylation of tRNAs with fluorinated amino acids for in vitro protein mutagenesis,” Beilstein J Org Chem. Apr. 20, 2010;6(40).
[cited by applicant]
Zoncu et al., “mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H(+)-ATPase,” Science. Nov. 4, 2011;334(6056):678-83.
[cited by applicant]
Threlfall, “Analysis of Organic Polymoprhs a Review,” Analyst, Oct. 1995, vol. 120, pp. 2435-2460.
[cited by applicant]
Byrn, “Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations,” Pharmaceutical Research, USA, Kluwer Academic Publishers, Jul. 1, 1995, vol. 12, No. 7, pp. 945-954.
[cited by applicant]
Oshima, “Crystallization of Polymorphs and Pseudo-Polymorphs and its Control,” Pharm Stage, 2007, vol. 6, No. 10, pp. 48-53.
[cited by applicant]
Caira, M. R., “Crystalline Polymorphism of Organic Compounds”, Topics in Current Chemistry, 1998, vol. 198, pp. 163-208; Springer Verlag, Berlin, Heidelberg.https://doi.org/10.1007/3-540-69178-2_5, first available onlin…
[cited by applicant]
Database PubChem [online], PubChem CID 12425333, Feb. 8, 2007.
[cited by applicant]
Database PubChem [online], PubChem CID 12425335, Feb. 8, 2007.
[cited by applicant]
Database PubChem [online], PubChem CID 71334221, May 21, 2013.
[cited by applicant]
Database PubChem [online], PubChem CID 45082328, Mar. 30, 2010.
[cited by applicant]
Database PubChem [online], PubChem CID 10607912, Oct. 25, 2006.
[cited by applicant]
Database PubChem [online], PubChem CID 22329417, Dec. 5, 2007.
[cited by applicant]
Database PubChem [online], PubChem CID 117532356, Feb. 15, 2016.
[cited by applicant]
Database PubChem [online], PubChem CID 76590157, Aug. 3, 2014.
[cited by applicant]
Database PubChem [online], PubChem CID 57677193, Aug. 19, 2012.
[cited by applicant]
Navitor Pharmaceuticals, Inc. (Sponsor): Anonymous, “Safety, Tolerability, PK and Efficacy of Single Doses of NV-5138 in Healthy Volunteers and Subjects With Treatment-Resistant Depression,” Jul. 10, 2018, XP093089717, …
[cited by applicant]
PCT International Search Report and Written Opinion from PCT/US2016/058188 dated Mar. 17, 2017.
[cited by applicant]
European Search Report from European Patent Application No. 20882523.2 dated Oct. 19, 2023.
[cited by applicant]
Chen, Q. et al., “Indium-Mediated Diastereoselective Allylation of D- and L-Glyceraldimines With 4-Bromo-1,1,1-Trifluoro-2-Butene: Highly Stereoselective Synthesis . . . ,” Journal of Organic Chemistry, vol. 71, No. 10,…
[cited by applicant]
Andrés et al., “Diastereoselective Synthesis of Beta-Amino-Alpha-(trifluoromethyl) Alcohols from Homochiral Alpha-Dibenzylamino Aldehydes”, European Journal of Organic Chemistry, 2004, 2004(7):1558-1566.
[cited by applicant]
Arthur et al., “In Situ Deprotection and Incorporation of Unnatural Amino Acids during Cell-Free Protein Synthesis”, Chemistry—A European Journal, 2013, 19(21):6824-6830.
[cited by applicant]
Ayi et al., “Reaction of Hydrogen Fluoride in Pyridine Solution with cis-Cyano-2-and cis-Amido-2-aziridines. Preparation of Beta-fluoro-Alpha-amino Acids and Esters by Means of Acidic Hydrolysis and Alcoholysis of Beta-…
[cited by applicant]
Balbach et al., “Pharmaceutical evaluation of early development candidates ”The 100 mg approach, International Journal of Pharmaceutics, 2004, 275(1-2):1-12.
[cited by applicant]
Behrends et al., “New matrix metalloproteinase inhibitors based on Gamma-fluorinated Alpha-aminocarboxylic and Alpha-aminohydroxamic acids”, Bioorganic & Medicinal Chemistry, 2015, 23(13):3809-3818.
[cited by applicant]
Biava et al., “Biocatalytic synthesis of (2S)-5,5,5-trifluoroleucine and improved resolution into (2S,4S) and (2S,4R) diastereoisomers”, Tetrahedron Letters, 2013, 54(28):3662-3665.
[cited by applicant]
Bilgicer et al., “A Coiled Coil with a Fluorous Core”, Journal of the American Chemical Society, 2001, 123 (19):4393-4399.
[cited by applicant]
Cai, “Molecular Mechanisms of Amino Acid Regulation of mTORC1 Signaling Pathway”, Science, 2016, 47(5):385 (With English Abstract Only).
[cited by applicant]
Chiu et al., “The Mood Stabilizer Lithium Potentiates the Antidepressant-Like Effects and Ameliorates Oxidative Stress Induced by Acute Ketamine in a Mouse Model of Stress”, International Journal of Neuropsychopharmacol…
[cited by applicant]
Ikutani, “Studies of the N-Oxides of N,N-Dialkylamino Acids. I. The Syntheses of N, N-Dimethyl Neutral Amino Acids and Corresponding N-Oxides”, Bulletin of the Chemical Society of Japan, Jul. 1968, 41(7):1679-1681.
[cited by applicant]
Meixia et al., “A New Therapeutic Target for Depression—The mTOR Signaling Pathway”, Journal of Military Surgeon in Southwest China, Jan. 2013, 15(1):53-59 (7 pages of English Translation and 3 pages of Official Copy).
[cited by applicant]
Shmatova et al., “Friedel-Crafts alkylation of natural amino acid-derived pyrroles with CF3-substituted cyclic imines”, Mendeleev Communications, 2013, 23(2):92-93.
[cited by applicant]
Singhal et al., “Drug polymorphism and dosage form design: a practical perspective”, Advanced Drug Delivery Reviews, 2004, 56(3):335-347.
[cited by applicant]
Sorochinsky et al., “Chemical deracemization and (S) to (R) interconversion of some fluorine-containing alpha-amino acids”, Journal of Fluorine Chemistry, 2013, 152:114-118.
[cited by applicant]
International Search Report and Written Opinion received for PCT Application No. PCT/US2023/036588, mailed on Feb. 12, 2024, 6 pages.
[cited by applicant]